A notable example is the immune checkpoint inhibitor pembrolizumab (Keytruda), a PD-L1 inhibitor approved to treat cervical cancer that has recurred or spread during or after chemotherapy, particularly in cases where the tumor expresses PD-L1. Here, CD274 is linked to cervical carcinoma.